Natural history studies are central to rare disease research. Rare diseases are defined as conditions that affect less than 1 in 200,000 people in the US or les...
Continue reading
On the most recent episode of The Genetics Podcast, Patrick speaks with Samuli Ripatti, director of the Institute for Molecular Medicine Finland (FIMM) and prof...
Continue reading
On the latest episode of The Genetics Podcast, Patrick sat down with Jonathan Marchini, Head of Statistical Genetics & Machine Learning at the Regeneron Gen...
Continue reading
On the latest episode of The Genetics Podcast, Patrick speaks with Max Bronstein, founder and CEO of Aviva Strategies, a health policy firm dedicated to support...
Continue reading
Genetic medicines have been advancing at an extraordinary pace. Following the first wave of adeno-associated virus (AAV)–based gene therapies, the toolbox for g...
Continue reading
The next generation of advanced therapies, particularly gene therapies, hold enormous promise for patients with rare conditions. However, their clinical develop...
Continue reading
In this week’s episode of The Genetics Podcast, we spoke with Richard Wilson, Senior Vice President and Primary Focus Lead for Genetic Regulation at Astellas, a...
Continue reading
Precision medicine trials increasingly depend on genetic or biomarker testing to determine eligibility. Each additional test introduces operational complexity: ...
Continue reading
In rare disease, families are often forced into roles that extend far beyond caregiving. When faced with diseases for which no treatment exists, parents have of...
Continue reading
Last week marked a major milestone for The Genetics Podcast: our 200th episode. To celebrate, host Patrick Short revisited some of the most impactful conversati...
Continue reading